-
公开(公告)号:US06706715B2
公开(公告)日:2004-03-16
申请号:US10183848
申请日:2002-06-26
申请人: Manfred Schudok , Otmar Klingler , Hans-Peter Nestler , Hans Matter , Herman Schreuder , Hauke Szillat
发明人: Manfred Schudok , Otmar Klingler , Hans-Peter Nestler , Hans Matter , Herman Schreuder , Hauke Szillat
IPC分类号: A61K314425
CPC分类号: C07C275/42 , C07C2601/14 , C07D333/38
摘要: The present invention relates to compounds of the formula I, in which R1, R2, R4, R5, D1, D2, X1, X2, X3, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
摘要翻译: 本发明涉及式I化合物,其中R 1,R 2,R 4,R 5,D 1,D 2,X 1,X 2,X 3,A和B具有所指定的含义 在权利要求中。 式I的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用,并且适用于例如治疗和预防血栓栓塞性疾病和再狭窄。 它们是血液凝固酶因子VIIa的可逆抑制剂,并且通常可以在其中存在不需要的因子VIIa的活性或用于治疗或预防因子VIIa的抑制的条件下使用。 本发明还涉及式I化合物的制备方法,其用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。
-
公开(公告)号:US08143242B2
公开(公告)日:2012-03-27
申请号:US12683736
申请日:2010-01-07
申请人: Henning Steinhagen , Hauke Szillat , Markus Follmann , Reinhard Kirsch , Volkmar Wehner , Hans Matter , Martin Lorenz , Kent W. Neuenschwander , Anthony C. Scotese
发明人: Henning Steinhagen , Hauke Szillat , Markus Follmann , Reinhard Kirsch , Volkmar Wehner , Hans Matter , Martin Lorenz , Kent W. Neuenschwander , Anthony C. Scotese
IPC分类号: A61K31/553 , A61K31/4965 , A61K31/44 , A61K31/426 , A61K31/381 , A61K31/167 , C07D281/06 , C07D241/04 , C07D213/65 , C07D277/24 , C07D409/02 , C07C237/20
CPC分类号: C07D213/80 , C07C257/18 , C07C311/08 , C07C311/46 , C07C317/22 , C07C317/32 , C07C2601/14 , C07D211/42 , C07D213/30 , C07D213/34 , C07D309/08 , C07D409/12 , C07D413/12
摘要: The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
摘要翻译: 本发明涉及式I化合物。式I化合物是有价值的药理学活性化合物。 它们表现出强烈的抗血栓形成作用,并且适用于治疗和预防心血管疾病如血栓栓塞性疾病或再狭窄。 它们是血液凝固酶,特别是因子VIIa的抑制剂,并且通常可用于其中存在不需要的因子VIIa的活性或用于治疗或预防因子VIIa的抑制的条件。 本发明还涉及制备式I化合物的方法,其用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。
-
公开(公告)号:US08710232B2
公开(公告)日:2014-04-29
申请号:US11551975
申请日:2006-10-23
IPC分类号: C07D401/12
CPC分类号: C07D401/06 , C07D401/14 , C07D409/14 , C07D417/06
摘要: The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式(I)化合物适用于制备用于预防和治疗伴有血栓形成,栓塞,高凝状态或纤维变化的疾病的药物。
-
公开(公告)号:US20070129341A1
公开(公告)日:2007-06-07
申请号:US11551975
申请日:2006-10-23
IPC分类号: A61K31/55 , A61K31/5415 , A61K31/541 , A61K31/5377 , A61K31/52 , A61K31/4745 , A61K31/4709 , A61K31/4439 , A61K31/4178
CPC分类号: C07D401/06 , C07D401/14 , C07D409/14 , C07D417/06
摘要: The present invention relates to compounds of formula (I) which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译: 本发明涉及作为活化凝血酶激活性纤维蛋白溶解抑制剂抑制剂的式(I)化合物。 式(I)化合物适用于制备用于预防和治疗伴有血栓形成,栓塞,高凝状态或纤维变化的疾病的药物。
-
-
-